Johnson & Johnson
Johnson & Johnson Reports Q4 and Full-Year 2024 Financial Results and Provides 2025 Guidance
Summary
Johnson & Johnson reported Q4 2024 sales growth of 5.3% to $22.5 billion, with operational growth of 6.7% and adjusted operational growth of 5.7%. The company's full-year 2024 sales were $88.8 billion, up 4.3% with operational growth of 5.9% and adjusted operational growth of 5.4%. Johnson & Johnson provided 2025 guidance for operational sales growth of 2.5% to 3.5% and adjusted operational EPS of $10.75 to $10.95.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement